The head and shoulders pattern successfully played out, with 
NOVO_B reaching my full target at 670.
Check out my original post:
The stock experienced a significant drop, falling as much as 27% on the Friday before Christmas. This was triggered by test results for their obesity drug, CagriSema, which showed patient weight loss of 22.7% - below the anticipated 25%.
I believe this reaction is an overcorrection and have taken advantage of this rare opportunity to purchaseNOVO_B, first at 680 and again at 600. I now plan to hold patiently, expecting Novo Nordisk to reach new all-time highs in the coming years.
NOVO_B reaching my full target at 670.Check out my original post:
The stock experienced a significant drop, falling as much as 27% on the Friday before Christmas. This was triggered by test results for their obesity drug, CagriSema, which showed patient weight loss of 22.7% - below the anticipated 25%.
I believe this reaction is an overcorrection and have taken advantage of this rare opportunity to purchase
NOVO_B, first at 680 and again at 600. I now plan to hold patiently, expecting Novo Nordisk to reach new all-time highs in the coming years.
Pubblicazioni correlate
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.
Pubblicazioni correlate
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.